Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

SAN FRANCISCO -- As more people are eligible to get vaccinated, reports of side effects after the second Pfizer and Moderna shots are surfacing. Dr. Robert Wachter, chief of medicine at UCSF says many ...

Nov 18 (Reuters) - COVID-19 vaccines from Pfizer Inc (PFE.N), opens new tab and Moderna Inc (MRNA.O), opens new tab could be ready for U.S. authorization and distribution within weeks, setting the ...

CHICAGO (WLS) -- The Johnson & Johnson vaccine continues to be put on hold after a CDC panel said it needs more time to look into claims of dangerous blood clots. The United Center mass vaccination ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...